Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby, Brian L Schmidt, Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby, Brian L Schmidt
Abstract
Background: Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression.
Methods: In this double-blind, placebo-controlled, crossover trial, 29 patients with cancer-related anxiety and depression were randomly assigned and received treatment with single-dose psilocybin (0.3 mg/kg) or niacin, both in conjunction with psychotherapy. The primary outcomes were anxiety and depression assessed between groups prior to the crossover at 7 weeks.
Results: Prior to the crossover, psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness, improved spiritual wellbeing, and increased quality of life. At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60-80% of participants continued with clinically significant reductions in depression or anxiety), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression.
Conclusions: In conjunction with psychotherapy, single moderate-dose psilocybin produced rapid, robust and enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress.
Trial registration: ClinicalTrials.gov Identifier: NCT00957359.
Keywords: Psilocybin; anxiety; cancer; depression; mystical experience; psychedelic.
Conflict of interest statement
Declaration of conflicting interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
© The Author(s) 2016.
Figures
References
- Aghajanian GK, Marek GJ. (1997) Serotonin induces excitatory postsynaptic potential in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36: 589–599.
- Arrieta O, Angulo LP, Nunez-Valencia C, et al. (2013) Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol 20(6): 1941–1948.
- Barrett FS, Johnson MW, Griffiths RR. (2015) Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol (Oxford, England) 29(11): 1182–1190.
- Beck AT, Steer RA, Garbin MG. (1988) Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psych Rev 8: 77–100.
- Berman MG, Peltier S, Nee DE, et al. (2011) Depression, rumination and the default network. Soc Cogn Affect Neurosci 6: 548–555.
- Bhagwagar Z, Hinz R, Taylor M, et al. , (2006) Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am J Psychiatry 163: 1580–1587.
- Bogenschutz MP, Johnson MW. (2016) Classic halluciongens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry 64: 250–258.
- Bogenschutz MP, Forcehimes AA, Pommy JA, et al. (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29(3): 289–299.
- Brady M, Peterman AH, Fitchett G, et al. (1999) A case for including spirituality in quality of life measurement in oncology. Psychooncology 8(5): 417–428.
- Breitbart W, Rosenfeld B, Gibson C, et al. (2010) Meaning-centered group psychotherapy for patients with advanced cancer: a pilot randomized controlled trial. Psychooncology 19(1): 21–28.
- Breitbart W, Rosenfeld B, Pessin H, et al. (2000) Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 284(22): 2907–2911.
- Brown KW, Levy AR, Rosberger Z, et al. (2003) Psychological distress and cancer survival: a follow-up 10 years after diagnosis. Psychosom Med 65: 636–643.
- Carbonaro TM, Bradsteet PM, Barrett FS, et al. (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol 30: 1268-1278.
- Carhart-Harris RL, Bolstridge M, Rucker J, et al. (2016) Psilocybin with psychological support for treatment- resistant depression: an open-label feasibility study. Lancet Psychiatry 3: 619-627.
- Carhart-Harris RL, Erritzoe D, Williams T, et al. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci 109(6): 2138–2143.
- Carhart-Harris RL, Leech R, Hellyer PJ, et al. (2014) The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 8: 20.
- Cohen H. (2005) Anxiolytic effect and memory improvement in rats by antisense oligodeoxynucleotide to 5 hydroxytryptamine-2A precursor protein. Depress Anxiety 22: 84–93.
- Deakin JF, Lees J, McKie S, et al. (2008) Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 65: 154–164.
- DeWilde KE, Levitch CF, Murrough JW, et al. (2015) The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann NY Acad Sci 1345: 47–58.
- Doblin R. (1991) Pahnke’s ‘Good Friday Experiment’: a long-term follow-up and methodological critique. J Transpersonal Psychol 23(1): 1–28.
- Drevets WC, Price JL, Furey ML. (2008) Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 213: 93–118.
- Duman RS. (2004) Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 5(1): 11–25.
- Farb NA, Anderson AK, Block RT, et al. (2011) Mood-linked responses in medial prefrontal cortex predict relapse in patients with recurrent unipolar depression. Biol Psychiatry 70: 366–372.
- Freedman R. (2010) Abrupt withdrawal of antidepressant treatment. Am J Psychiatry 167(8): 886–888.
- Frokjaer VG, Mortensen EL, Nielsen FA, et al. (2008) Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry 63(6): 569–576.
- Garcia-Romeu A, Griffiths RR, Johnson MW. (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 7(3): 157–164.
- Gasser P, Holstein D, Michel Y, et al. (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202(7): 513–520.
- Gomez-Gil E, Gasto C, Carretero M, et al. (2004) Decrease of the platelet 5-HT2A receptor function by long-term imipramine treatment in endogenous depression. Hum Psychopharmacol 19(4): 251–258.
- Grassi L, Caruso R, Hammelef K, et al. (2014) Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review. Int Rev Psychiatry 26(1): 44–62.
- Grecius MD, Krasnow B, Reiss AL, et al. (2007) Resting-state functional connectivity in major depression: abnormally increased contributions from the subgenual cingulate cortex and thalamus. Biol Psychiatry 62: 429–437.
- Griffiths RR, Johnson MW, Richards WA, et al. (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 218(4): 649–665.
- Griffiths RR, Richards WA, Johnson MW, et al. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22(6): 621–632.
- Griffiths RR, Richards WA, McCann U, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187(3): 268–283; discussion 284–292.
- Grob CS, Bossis AP, Griffiths RR. (2013) Use of the classical hallucinogen psilocybin for treatment of existential distress associated with cancer. In: Carr BI, Steel J. (eds) Psychological Aspects of Cancer. New York: Springer.
- Grob CS, Danforth AL, Chopra GS, et al. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68(1): 71–78.
- Grof S, Halifax J. (1977) The Human Encounter with Death. New York: E.P. Dutton.
- Grof S, Goodman LE, Richards WA, et al. (1973) LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 8(3): 129–144.
- Hayes AF. (2013) Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach. New York: Guilford.
- Holtzheimer PE, Mayberg HS. (2011) Stuck in a rut: rethinking depression and its treatment. Trend Neurosci 34: 1–9.
- Hsu WL, Chung HW, Wu CY, et al. (2015) Glutamate stimulates local protein synthesis in the axons or rat cortical neurons by activating α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and metabotropic glutamate receptors. J Biol Chem 290(34): 20748–20760.
- Hung CI, Liu CY, Wang SJ, et al. (2012) The cut-off points of the Depression and Somatic Symptoms Scale and the Hospital Anxiety and Depression Scale in detecting non-full remission and a current major depressive episode. Int J Psychiatry Clin Pract 16(1): 33–40.
- Iovieno N, Tedschini E, Ameral VE, et al. (2011) Antidepressants for major depressive disorder in patients with co-morbid axis-III disorder: a meta-analyses of patient characteristics and placebo response rates in randomized controlled trials. Int Clin Psychopharmacol 26: 69–74.
- Jaiswal R, Alici Y, Breitbart W. (2014) A comprehensive review of palliative care in patients with cancer. Int Rev Psychiatry 26(1): 87–101.
- Johnson MW, Garcia-Romeu A, Cosimano MP, et al. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28(11): 983–992.
- Johnson MW, Richards W, Griffiths R. (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22(6): 603–620.
- Kast E. (1966) LSD and the dying patient. Chic Med Sch Q 26: 80–87.
- Kast EC, Collins VJ. (1964) Study of lysergic acid diethylamide as an analgesic agent. Anesth Analg 43: 285–291.
- Kennedy SH, Konarski JZ, Segal ZV, et al. (2007) Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry 164: 778–788.
- Kissane DW, Wein S, Love A, et al. (2004) The demoralization scale: a report of its development and preliminary validation. J Palliat Care 20(4): 269–276.
- Krebs TS, Johansen PO. (2012) Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials; J Psychopharmacol 26(7): 994–1002.
- Krebs TS, Johansen PO. (2013) Psychedelics and mental health: a population study. PLoS One 19; 8(8): e63972.
- Laoutidis ZG, Mathiak K. (2013) Antidepressants in the treatment of depression/depressive symptoms in cancer patients. A systematic review and meta-analysis. BMC Psychiatry 13: 140.
- Lemay K, Wilson KG. (2008) Treatment of existential distress in life threatening illness: a review of manualized interventions. Clin Psychol Rev 28(3): 472–493.
- Lepack AE, Fuchikami M, Dwyer JM, et al. (2014) BDNF release is required for behavioral actions of ketamine. Int J Neuropsychopharmacol 18: 1–6.
- Li X, Frye MA, Shelton RC. (2012) Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology 37(1): 77–101.
- McClain CS, Rosenfeld B, Breitbart W. (2003) Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. Lancet 361(9369): 1603–1607.
- MacLean KA, Leoutsakos JM, Johnson MW, et al. (2012) Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig 51(4): 721–737.
- Mendelson SD. (2000) The current status of the platelet 5-HT(2A) receptor in depression. J Affect Disord 57: 13–24.
- Meyer JH. (2012) Neuroimaging markers of cellular function in major depression disorder: implications for therapeutics, personalized medicine, and prevention. Clin Pharmacol Ther 91: 201–214.
- Meyer JH, McMain S, Kennedy SH, et al. (2003) Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 160: 90–99.
- Mitchell AJ, Chan M, Bhatt H, et al. (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12: 160–174.
- NCCN (National Comprehensive Cancer Network) (2014) Clinical practice guidelines in oncology: distress management (version I.2014). Available at: .
- Nelson CJ, Rosenfeld B, Breitbart W, et al. (2002) Spirituality, religion, and depression in the terminally Ill. Psychosomatics 43(3): 213–220.
- Nic Dhonnchadha BA, Hascoet M, Jolliet P, et al. (2003) Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice. Behav Brain Res 147: 175–184.
- Nichols DE. (2015) Psychedelics. Pharmacolog Rev 68: 264–355.
- Osorio FL, Sanches RF, Macedo LR, et al. (2015) Antidepressant effects of single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr 37(1): 13–20.
- Ostuzzi G, Matcham F, Dauchy S, et al. (2015) Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev 6: CD011006.
- Pahnke WN. (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness, PhD dissertation. Cambridge, MA: Harvard University.
- Pahnke WN, Kurland AA, Goodman LE, et al. (1969) LSD-assisted psychotherapy with terminal cancer patients. Curr Psychiatr Ther 9: 144–152.
- Pandey GN, Dwivedi Y, Rizavi HS, et al. (2002) Higher expression of serotonin 5-HT (2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry 159: 419–429.
- Puchalski CM. (2012) Spirituality in the cancer trajectory. Ann Oncol 23 (Suppl 3): 49–55.
- Reeves GM, Rohan KJ, Langenberg P, et al. (2012) Calibration of response and remission cut-points on the Beck Depression Inventory- Second Edition for monitoring seasonal affective disorder treatment outcomes. J Affect Disord 138(1–2): 123–127.
- Riedel M, Moller HJ, Obermeier M, et al. (2010) Response and remission criteria in major depression—a validation of current practice. J Psychiatr Res 44(15): 1063–1068.
- Ripoll N, Hascoet M, Bourin M. (2006) Implication of 5-HT2A subtype receptors in DOI activity in the four plates test–retest paradigm in mice. Behav Brain Res 166: 131–139.
- Ripoll N, Nic Dhonnchadha BA, Sebille V, et al. (2005) The four-plates test–retest paradigm to discriminate anxiolytic effects. Psychopharmacology (Berl) 180: 73–83.
- Rosenfeld B, Pessin H, Lewis C. (2011) Assessing hopelessness in terminally ill cancer patients: development of the Hopelessness Assessment in Illness Questionnaire. Psychol Assess 23(2): 325–336.
- Ross S. (2012) Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatric Clin North Am 35(2): 357–374.
- Sen S, Duman R, Sanacora G. (2008) Serum brain-derived neurotrophic factor, depression and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64(6): 527–532.
- Shelton RC, Sanders-Bush E, Manier DH, et al. (2009) Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 158: 1406–1415.
- Shimizu E, Hashimoto K, Okamura N, et al. (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54(1): 70–75.
- Spielberger CD. (1983) Manual for the state-trait anxiety inventory (Self-Evaluation Questionnaire). Palo Alto, CA: Consulting Psychologists Press, Inc.
- Studerus E, Kometer M, Hasler F, et al. (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25: 1434–1452.
- Templer DI. (1970) The construction and validation of a death anxiety scale. J Gen Psychol 82: 165–177.
- Vaidya VA, Marek GJ, Aghajanian GK, et al. (1997) 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17(8): 2785–2795.
- VandeCreek L. (1999) The death transcendence scale. In: Hill PC, Hood RW. (eds) Measures of religiosity. Birmingham, AL: Religious Education Press, pp. 442–445.
- Vollenweider FX, Kometer M. (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11(9): 642–651.
- Weisstaub NV, Zhou M, Lira A, et al. (2006) Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 313(5786): 536–540.
- WHO (World Health Organization) (1994) Development of the WHOQOL: rationale and current status. Int J Ment Health 23(3): 24–56.
- Yamauchi M, Miyara T, Matsushima T, et al. (2006) Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res 1067(1): 164–169.
- Zanos P, Moaddel R, Morris PJ, et al. (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533(7604): 481–486.
- Zigmond AS, Snaith RP. (1983) The hospital anxiety and depression scale. Acta Psychiatrica Scand 67(6): 361–370.
Source: PubMed